Efficacy of doxorubicin coupled to lactosaminated albumin on rat hepatocellular carcinomas evaluated by ultrasound imaging

Digestive and Liver Disease

Volumn 40, Issue 4, 2008, Pages 278-284

  Di Stefano, G ^a   Fiume, L ^a   Baglioni, M ^a   Bolondi, L ^b   Chieco, P ^b   Kratz, F ^c   Pariali, M ^b   Rubini, G ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c TUMOR BIOLOGY CENTER   (Germany)

Author keywords

Drug targeting; HCC chemotherapy; HCC targeted doxorubicin; Rat HCC imaging; Ultrasonography of rat liver

Indexed keywords

DIETHYLNITROSAMINE; DOXORUBICIN; HUMAN SERUM ALBUMIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; ECHOGRAPHY; LIVER CELL CARCINOMA; MALE; NONHUMAN; RAT; SINGLE DRUG DOSE; SYSTEMIC THERAPY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DIETHYLNITROSAMINE; DOXORUBICIN; DRUG CARRIERS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; RATS; SERUM ALBUMIN;

EID: 39749196828     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2007.10.008     Document Type: Article

References (27)

1. Hyodo I., Mizuno M., Yamada G., and Tsuji T. Distribution of asialoglycoprotein receptor in human hepatocellular carcinoma. Liver 13 (1993) 80-85
2. Trerè D., Fiume L., Badiali De Giorgi L., Di Stefano G., Migaldi M., and Derenzini M. The asialoglycoprotein receptor in human hepatocellular carcinomas: its expression on proliferating cells. Br J Cancer 81 (1999) 404-408
3. Di Stefano G., Kratz F., Lanza M., and Fiume L. Doxorubicin coupled to lactosaminated human albumin remains confined within mouse liver cells after the intracellular release from the carrier. Dig Liver Dis 35 (2003) 428-433
4. Ashwell G., and Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem 51 (1982) 531-534
5. Fiume L., Mattioli A., Balboni P.G., Tognon M., Barbanti-Brodano G., de Vries J., et al. Enhanced inhibition of virus DNA synthesis in hepatocytes by trifluorothymidine coupled to asialofetuin. FEBS Lett 103 (1979) 47-51
6. Wilson G. Effect of reductive lactosamination on the hepatic uptake of bovine pancreatic ribonuclease A dimer. J Biol Chem 253 (1978) 2070-2072
7. Fiume L., Busi C., Mattioli A., and Barbanti-Brodano G. Hepatocyte targeting of adenine-9-β-D-arabinofuranoside 5′-monophosphate (ara-AMP) coupled to lactosaminated albumin. FEBS Lett 129 (1981) 261-264
8. Fiume L., Bassi B., Busi C., Mattioli A., and Spinosa G. Drug targeting in antiviral chemotherapy. A chemically stable conjugate of 9-β-D-arabinofuranosyladenine 5′-monophosphate with lactosaminated albumin accomplishes a selective delivery of the drug to liver cells. Biochem Pharmacol 35 (1986) 967-972
9. Jansen R.W., Kruijt J., van Berkel T.J.C., and Meijer D.K.F. Coupling of the antiviral drug ara-AMP to lactosaminated albumin leads to a specific uptake in rat and human hepatocytes. Hepatology 18 (1993) 146-152
10. Fiume L., Torrani Cerenzia M.R., Bonino F., Busi C., Mattioli A., Brunetto M.R., et al. Inhibition of hepatitis B virus replication by vidarabine monophosphate conjugated with lactosaminated serum albumin. Lancet 2 (1988) 13-15
11. Torrani Cerenzia M.R., Fiume L., De Bernardi Venon W., Lavezzo B., Brunetto M.R., Ponzetto A., et al. Adenine arabinoside monophosphate coupled to lactosaminated albumin, administered for 4 weeks to patients with chronic type B hepatitis, decreased viremia without producing significant side effects. Hepatology 23 (1996) 657-661
12. Zarski J.P., Barange K., Souvignet C., Bertini M., Marcellin P., Tran A., et al. Efficacy and safety of L-HSA-ara-AMP in chronic hepatitis B patients non responder to interferon therapy: a randomised clinical trial. J Hepatol 34 (2001) 487-488
13. Di Stefano G., Lanza M., Kratz F., Merina L., and Fiume L. A novel method for coupling doxorubicin to lactosaminated human albumin by an acid sensitive hydrazone bond: synthesis, characterization and preliminary biological properties of the conjugate. Eur J Pharm Sci 23 (2004) 393-397
14. Willner D., Trail P.A., Hofstead S.J., King H.D., Lasch S.J., Braslawsky G.R., et al. (6-Maleimidocaproyl)hydrazone derivative of doxorubicin-a new derivative for the preparation of immunoconjugates of doxorubicin. Bioconjug Chem 4 (1993) 521-527
15. Greenfield R.S., Kaneko T., Daues A., Edson M.A., Fitzgerald K.A., Olech L.J., et al. Evaluation in vitro of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linker. Cancer Res 50 (1990) 6600-6607
16. Rajewsky M.F., Dauber W., and Frankenberg H. Liver carcinogenesis by diethylnitrosamine in the rat. Science 152 (1966) 83-85
17. Di Stefano G., Fiume L., Bolondi L., Lanza M., Pariali M., and Chieco P. Enhanced uptake of lactosaminated human albumin by rat hepatocarcinomas: implications for an improved chemotherapy of primary liver tumours. Liver Int 25 (2005) 854-860
18. Di Stefano G., Fiume L., Baglioni M., Bolondi L., Busi C., Chieco P., et al. A conjugate of doxorubicin with lactosaminated albumin enhances the drug concentrations in all the forms of rat hepatocellular carcinomas independently of their differentiation grade. Liver Int 26 (2006) 726-733
19. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 (2003) 1907-2191
20. Di Stefano G., Fiume L., Baglioni M., Busi C., Chieco P., Kratz F., et al. Coupling of lactose molecules to the carrier protein hinders the spleen and bone marrow uptake of doxorubicin conjugated with human albumin. Eur J Pharm Sci 30 (2007) 136-142
21. Fiume L., Bolondi L., Busi C., Chieco P., Kratz F., Lanza M., et al. Doxorubicin coupled to lactosaminated albumin inhibits the growth of hepatocellular carcinomas induced in rats by diethylnitrosamine. J Hepatol 43 (2005) 645-652
22. Graham K.C., Wirtzfeld L.A., MacKenzie L.T., Postenka C.O., Groom A.C., MacDonald I.C., et al. Three-dimensional high-frequency ultrasound imaging for longitudinal evaluation of liver metastases in preclinical models. Cancer Res 65 (2005) 5231-5237
23. Kratz F., Warnecke A., Scheuermann K., Stockmar C., Schwab J., Lazar P., et al. Probing the cysteine-34 position of endogenous serum albumin with thiol binding doxorubicin derivatives: improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to the parent compound. J Med Chem 45 (2002) 5523-5533
24. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall L.J. Protein measurement with the Folin phenol reagent. J Biol Chem 193 (1951) 265-275
25. Mazuè G., Iatropoulos M., Imondi A., Castellino S., Brughera M., Podestà A., et al. Anthracyclines: a review of general and special toxicity studies. Int J Oncol 7 (1995) 713-726
26. Ho C.L., Yu S.C.H., and Yeung D.W.C. 11C-Acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 44 (2003) 213-221
27. Di Stefano G., Fiume L., Domenicali M., Busi C., Chieco P., Kratz F., et al. Doxorubicin coupled to lactosaminated albumin: effects on rats with liver fibrosis and cirrhosis. Dig Liver Dis 38 (2006) 404-408